Respiratory syncytial virus (RSV) immunization is available to the following groups for the 2025/2026 respiratory season:
- Infants and high-risk children (Beyfortus® (Nirsevimab), or AbrysvoTM in pregnancy)
- Adults 75 years of age and older
- High risk adults 60 to 74 years of age
Primary care plays an especially important role in administering the RSV vaccine this season, particularly for the following groups who will have limited access to the vaccine from other settings:
- Infants born outside the hospital system (e.g., home births) or outside the RSV season (e.g., spring/summer births) or who refused hospital administration at birth
- High-risk children up to 24 months of age during their second RSV season
- Adults 75 years of age and older who are not hospitalized and do not live in a congregate setting (NOTE: these individuals cannot receive RSV vaccine from a pharmacy)
Billing for RSV Immunization
- The OMA has reiterated that RSV immunization is an insured physician service that is eligible for payment within existing codes
- Sample billing codes include: Immunization + Counselling (20 min – K013 (record start and stop time)
- For more detailed RSV immunization billing information, visit the OMA’s RSV Prevention Programs and scroll down to “Billing”.
- NEW: Effective Oct. 1, 2025, the Ministry has introduced a new diagnostic code ‘489 – RSV Respiratory syncytial virus’, to be used for RSV immunization or diagnosis of RSV. More information.
More Information:
English 